This is your brain on pandemic: What chronic stress is doing to us
Back in the 1980s, there was a public service announcement on TV that you may remember — or may have seen on YouTube. A guy in a kitchen held up an egg and said, "This is your brain." Then he cracked the egg into a hot frying pan, and said, "This is your brain on drugs." One year into this pandemic, your brain might be feeling a bit like that egg: Fried. "Everything is so much harder," said Stephanie Johnson, a client relationship executive who lives in Toronto. "I don't have the motivation that I used to have. I don't have the efficiency that I used to have." "Defeated" is how Vas Smountas, a freelance graphic designer, describes it. Also living in Toronto, she describes herself these days as "tired, defeated, foggy, unmotivated." And research suggests those feelings are not uncommon right now,...
Pandemic Parenting: Experts on Helping Children Get Past Their Germ Fear
TORONTO -- A year ago, many Canadians were washing down any package that came to the door. Now we’re tearing with abandon into that Amazon box before the masked delivery driver has even left the front porch. But for some, a year’s worth of timed handwashing and pushing crosswalk buttons with our elbows has caused significant stress that won’t be so easy to cast aside when the world turns back to normal. This is particularly true for children who are prone to anxiety. “Certainly (the pandemic) is causing significant distress in kids,” says Dr. Sandra Mendlowitz, a psychologist and co-founder of Reframe Psychology Clinic in Toronto, which focuses on anxiety disorders, depression and obsessive-compulsive disorder (OCD) in children. “Part of being a child is to have lots of social interactions and learn from that, so I think that it's kind...
BRAXIA SCIENTIFIC LAUNCHES PSILOCYBIN-ASSISTED CLINICAL THERAPY TRAINING PROGRAM
BRAXIA SCIENTIFIC LAUNCHES PSILOCYBIN-ASSISTED CLINICAL THERAPY TRAINING PROGRAM TO DEVELOP NEW GENERATION OF QUALIFIED PHYSICIANS, PSYCHOTHERAPISTS AND PSYCHOLOGISTS FOR MENTAL HEALTH TORONTO, ONTARIO June 29, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce it has launched its psilocybin-assisted clinical therapy training program. Through this program, Braxia will develop, train and support a new generation of qualified, skilled in best practices independent medical physicians, psychologists and psychotherapists to implement safe and effective psilocybin-assisted therapy for patients with depression. The therapists will participate in the provision of psychotherapy in upcoming clinical trials at Braxia evaluating the safety and efficacy of psilocybin in depression. The Company anticipates that, pending regulatory approval of psilocybin, therapists would also be...
TRAINING PROGRAM ENROLLMENT FOR SEPTEMBER 2021
Braxia Institute Psilocybin-Assisted Therapy Training Program Request for Applications for Class of 2022 Application Deadline: July 11, 2021 Tentative Program Start Date: September 2021 (pandemic permitting) A total of 14 qualified therapists will be selected for the training program. The training program will include didactic teaching, peer teaching, group discussion and simulations followed by a practicum component. The practicum component will include administering psilocybin-assisted therapy for participants with depression as part of a Health Canada approved clinical trial. We hope to recruit an interdisciplinary group of physicians, psychologists and psychotherapists. Therapists will work in dyads, pairing physician therapists with non-physician therapists as at least one physician is required for all psilocybin doses administered. You will receive group peer-supervision throughout the program. The goal of the course is to become fully competent to perform psilocybin-assisted therapy for future clinical trials and possibly clinical...
ENROLLMENT FOR SEPTEMBER 2021
BRAXIA INSTITUTE TRAINING PROGRAM ENROLLMENT FOR SEPTEMBER 2021 Braxia Institute Psilocybin-Assisted Therapy Training Program Request for Applications for Class of 2022 A total of 14 qualified therapists will be selected for the training program. The training program will include didactic teaching, peer teaching, group discussion and simulations followed by a practicum component. The practicum component will include administering psilocybin-assisted therapy for participants with depression as part of a Health Canada approved clinical trial. We hope to recruit an interdisciplinary group of physicians, psychologists and psychotherapists. Therapists will work in dyads, pairing physician therapists with non-physician therapists as at least one physician is required for all psilocybin doses administered. You will receive group peer-supervision throughout the program. The goal of the course is to become fully competent to perform psilocybin-assisted therapy for future clinical trials and possibly clinical care, if psilocybin...
Dr. Roger McIntyre @ H.C. Wainwright Virtual Conference Presentation
The Patient Experience and Commercial Considerations When Launching Psychoactive Agents in Psychiatry
WEBCAST ALERT: H.C. WAINWRIGHT & CO.
WEBCAST ALERT: H.C. WAINWRIGHT VIRTUAL CONFERENCE PRESENTATION WEBCAST ALERT Dr. Roger McIntyre @ H.C. Wainwright Virtual Conference Presentation The Patient Experience and Commercial Considerations When Launching Psychoactive Agents in Psychiatry Tune in Live on Thursday, 6/17 at 2:00 PM (Eastern Standard Time) Webcast link is closed. Symbols – CSE: BRAX OTC: BRAXF FWB: 496
PSYCHEDELICS IN PSYCHIATRY AND BEYOND
BRAXIA SCIENTIFIC TO PRESENT AT THE PSYCHEDELICS IN PSYCHIATRY AND BEYOND VIRTUAL CONFERENCE HOSTED BY H.C. WAINWRIGHT & CO. ON JUNE 17, 2021 TORONTO, ONTARIO June 9, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce its participation at the upcoming Psychedelics in Psychiatry and Beyond Virtual Conference, hosted by H.C. Wainwright & Co. on June 17, 2021. Braxia’s CEO, Dr. Roger McIntyre will present and participate in a panel discussion, “Patient Experience And Commercial Considerations When Launching Psychoactive Agents In Psychiatry.” Dr. McIntyre will also be available to host virtual one-on-one meetings with institutional investors registered with H.C. Wainwright and Co. For additional information on the conference please visit: https://hcwevents.com/psychedelics/ About Braxia Scientific Corp. Braxia Scientific is a...
KETAMINE AND ESKETAMINE TREATMENT GUIDANCE
AMERICAN JOURNAL OF PSYCHIATRY PUBLISHES INTERNATIONAL KETAMINE AND ESKETAMINE TREATMENT GUIDANCE LED BY BRAXIA SCIENTIFIC CEO DR. ROGER MCINTYRE International Expert Opinion and Implementation Guidance outlines Ketamine and Esketamine treatment parameters setting the standard for the clinical implementation of these rapid-acting treatments in treatment resistant depression Guidance published in the official Journal of the American Psychiatric Association establishes Braxia Scientific as an international leader in the rapidly evolving industry of Ketamine, Esketamine and rapid acting antidepressants TORONTO, ONTARIO June 9, 2021 – Braxia Scientific Corp. (“Braxia”, or the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a medical research company with clinics providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce the American Journal of Psychiatry, the most widely read psychiatric journal in the world, has published the International Expert Opinion and Implementation Guidance (the “Guidelines”) for the clinical use of...
DR. DAVID GREENBERG TO BOARD OF DIRECTORS
BRAXIA SCIENTIFIC APPOINTS DR. DAVID GREENBERG TO BOARD OF DIRECTORS TORONTO, ONTARIO May 31, 2021 – Braxia Scientific Corp. (the “Company”), (CSE: BRAX) (OTC: BRAXF) (FWB: 496), a research driven clinical platform developing and providing innovative ketamine treatments for persons with depression and related disorders, is pleased to announce it has appointed Dr. David Greenberg to its Board of Directors. A nationally recognized general medical practitioner for more than 30 years and a lecturer at The University of Toronto in the Department of Family and Community Medicine, Dr. David Greenberg brings extensive experience in Mental Health and Concussions. He has developed and implemented multiple education programs for medical practitioners, nationally and internationally, and is regarded as an international health expert and keynote speaker on the topic of depression and related disorders. Dr. Greenberg is the Team Physician for the Toronto Argonauts,...
The Current with Matt Galloway
Understanding pandemic burnout; why tackling deforestation could be key to stopping future viral outbreaks; Yukon enacts comprehensive transgender health care; and Canadian universities battling COVID-19 outbreaks Feeling tired? Unmotivated? You might be experiencing pandemic burnout. We discuss the impact of long-term stress on our brains and memory with Dr. Roger McIntyre, professor of psychiatry and pharmacology at the University of Toronto, and Dr. Natasha Rajah, professor in the department of psychiatry at McGill University and the Douglas Research Centre in Montreal. Then, as this pandemic drags on, scientists are already looking at how to prevent the next one — and some say a key factor will be tackling deforestation. We discuss why with Dr. Jonathan Epstein, a veterinarian and disease ecologist; Kimberly Fornace, an epidemiologist at the London School of Hygiene and Tropical Medicine; and Terry Sunderland, a professor of...
THE BRAXIA INSTITUTE
BRAXIA SCIENTIFIC INTRODUCES THE BRAXIA INSTITUTE Over 200 physicians and healthcare providers from Canada, U.S., and Asia to attend Braxia’s Symposium on rapid acting anti-depressants (RAAD) which include ketamine, esketamine and psychedelic therapies Braxia Institute aims to turn research into clinical action to achieve better outcomes for people with mental illness by closing the extraordinary gap between clinical practice and neuroscience research of ketamine and psychedelic treatment TORONTO, ONTARIO May 20, 2021 – Braxia Scientific Corp. (“Braxia Scientific” or the “Company”), (CSE: BRAX) (FWB: 496) (OTC: SHRMF), a research driven clinical platform developing and providing novel ketamine treatments for persons with depression and related disorders, is pleased to announce the launch of the Braxia Institute (“Braxia Institute”), the Company’s training Centre of Excellence focused on advancing psychiatric clinical practice and health services of ketamine and psychedelic treatment therapy for people with...